Search

Your search keyword '"Lauwers-Cances, Valerie"' showing total 48 results
Start Over Author "Lauwers-Cances, Valerie"
48 results on '"Lauwers-Cances, Valerie"'

1. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Author

Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel

Published
2022
Full Text
View/download PDF

2. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03

Author

Perrot, Aurore, Roussel, Murielle, Lauwers‐Cances, Valerie, Hulin, Cyrille, Leleu, Xavier, Touzeau, Cyrille, Facon, Thierry, Mariette, Clara, Schiano, Jean‐Marc, Gay, Julie, Montes, Lydia, Ranta, Dana, Huguet, Amandine, Wuillème, Soraya, Dejoie, Thomas, Devlamynck, Laure, Corre, Jill, Avet‐Loiseau, Hervé, Moreau, Philippe, and Attal, Michel

Subjects
MULTIPLE myeloma, LENALIDOMIDE, PERIPHERAL neuropathy, QUADRUPLETS, CLINICAL trials
Abstract

Summary: Therapeutic strategies for patients with newly diagnosed multiple myeloma (NDMM) have considerably improved during the last 10 years. The IFM2014‐03 trial proposed an all‐oral triplet induction/consolidation regimen in transplant‐eligible NDMM patients, followed by lenalidomide maintenance. Induction consisted of three 21‐day cycles of ixazomib, lenalidomide and dexamethasone (IRd), before high‐dose Melphalan with transplant followed by eight 28‐day cycles of IRd consolidation before 13 cycles of lenalidomide maintenance. Forty‐six patients were enrolled and received at least one dose of therapy, and 39 entered the maintenance phase. The primary end‐point was stringent complete response after consolidation, and was achieved in nine patients (20.9%, 90% CI 11.4–33.7; p = 0.998). Ten patients (24.4%) had an undetectable minimal residual disease. The overall response rate was 95.7%. The 3‐year progression‐free survival was 66.3%. No unexpected toxicities were recorded, and only eight patients suspended from any study drug. Of note, 21 (45.7%) patients reported peripheral neuropathy (PN) (grades 1–2 with no serious adverse events). IRd induction and consolidation with transplant before lenalidomide maintenance shows lower response rates compared to other triplet therapies. It could be an alternative for patients who require an all‐oral regimen and/or with pre‐existent PN, especially if quadruplet regimens including anti‐CD38 antibody are not available. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Author

Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Published
2018
Full Text
View/download PDF

6. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Author

Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, and Avet-Loiseau, Hervé

Published
2015
Full Text
View/download PDF

7. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Author

Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, and Avet-Loiseau, Herve

Published
2015
Full Text
View/download PDF

8. Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients

Author

Schavgoulidze, Anais, primary, Lauwers-Cances, Valerie, additional, Perrot, Aurore, additional, Cazaubiel, Titouan, additional, Chretien, Marie-Lorraine, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Stoppa, Anne-Marie, additional, Decaux, Olivier, additional, Belhadj, Karim, additional, Arnulf, Bertrand, additional, Mohty, Mohamad, additional, Ariette, Clara M, additional, Fohrer-Sonntag, Cecile, additional, Lenain, Pascal, additional, Marolleau, Jean-Pierre, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Orsini-Piocelle, Frederique, additional, Jaccard, Arnaud, additional, Roussel, Murielle, additional, Benboubker, Lotfi, additional, Eveillard, Jean-Richard, additional, Dib, Mamoun, additional, Divoux, Marion, additional, Attal, Michel, additional, Avet-Loiseau, Herve, additional, and Corre, Jill, additional

Published
2022
Full Text
View/download PDF

10. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia

Author

Bertoli, Sarah, Bérard, Emilie, Huguet, Françoise, Huynh, Anne, Tavitian, Suzanne, Vergez, François, Dobbelstein, Sophie, Dastugue, Nicole, Mansat-De Mas, Véronique, Delabesse, Eric, Duchayne, Eliane, Demur, Cécile, Sarry, Audrey, Lauwers-Cances, Valérie, Laurent, Guy, Attal, Michel, and Récher, Christian

Published
2013
Full Text
View/download PDF

17. Impact of social position on the effect of cardiovascular risk factors on self-rated health

Author

Delpierre, Cyrille, Lauwers-Cances, Valerie, Datta, Geetanjali D., Berkman, Lisa, and Lang, Thierry

Subjects
Academic achievement -- Influence, Cardiovascular diseases -- Risk factors, Cardiovascular diseases -- Demographic aspects, Self-evaluation -- Health aspects, Government, Health care industry
Abstract

Objectives. We assessed the impact of education level on the association between self-rated health and cardiovascular risk factors (blood pressure, glycosylated hemoglobin level, and total cholesterol and triglyceride levels). Methods. We used data from the National Health and Nutrition Examination Survey for the years 2001 through 2004 (4015 men and 4066 women). Multivariate analyses were performed with a logistic regression model. Results. After adjustment for age and ethnicity, among women with high glycosylated hemoglobin levels, the most-educated women had poorer self-rated health compared with the least-educated women (odds ratio [OR] =4.61; 95% confidence interval [CI]=2.90, 7.34 vs OR=2.59; 95% CI=1.60, 4.20, respectively; interaction test, P=0.06). The same was true among women with high cholesterol levels (OR=2.23; 95% CI=1.40, 3.56 vs OR=1.13; 95% CI=0.85, 1.49, respectively; interaction test, P=0.06). Among men, the impact of education level on the association between self-rated health and any cardiovascular risk factors (measured or self-reported) was not significant. Conclusions. The impact of cardiovascular risk factors on self-rated health was higher for highly educated women, which could lead to underestimation of health inequalities between socioeconomic groups when self-rated health is used as an indicator of objective health. (doi:10.2105/AJPH.2008.147934)

Published
2009

18. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Author

Roussel, Murielle, primary, Lauwers-Cances, Valerie, additional, Wuilleme, Soraya, additional, Belhadj, Karim, additional, Manier, Salomon, additional, Garderet, Laurent, additional, Escoffre-Barbe, Martine, additional, Mariette, Clara, additional, Benboubker, Lotfi, additional, Caillot, Denis, additional, Sonntag, Cécile, additional, Touzeau, Cyrille, additional, Dupuis, Jehan, additional, Moreau, Philippe, additional, Leleu, Xavier, additional, Facon, Thierry, additional, Hébraud, Benjamin, additional, Corre, Jill, additional, and Attal, Michel, additional

Published
2021
Full Text
View/download PDF

19. Randomised clinical trial for the cost–utility evaluation of two strategies of perineal reconstruction after abdominoperineal resection in the context of anorectal carcinoma: biological mesh repair versus primary perineal wound closure, study protocol for the GRECCAR 9 Study

Author

Buscail, Etienne, primary, Canivet, Cindy, additional, Ghouti, Laurent, additional, Kirzin, Sylvain, additional, Carrere, Nicolas, additional, Molinier, Laurent, additional, Rosillo, Aline, additional, Lauwers-Cances, Valerie, additional, and Costa, Nadège, additional

Published
2021
Full Text
View/download PDF

21. High-risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population

Author

Delpierre, Cyrille, Cuzin, Lise, Lauwers-Cances, Valerie, Marchou, Bruno, and Lang, Thierry

Subjects
France -- Health policy, HIV infection -- Diagnosis, HIV infection -- Statistics, HIV (Viruses) -- Risk factors, HIV testing -- Research, Health
Abstract

The aim of the study was to identify high-risk groups and the determinants of late HIV diagnosis in France in the era of highly active antiretroviral therapy (HAART), from January 1996 to June 2005. Informations were collected from an electronic medical record of all HIV-1-infected patients who sought care in six HIV reference centers in France, constituting a prospective multicentric cohort. Patients were defined as 'late testers' if they had presented with either symptoms of clinical AIDS or a CD4 cell count less than 200/[mm.sup.3] during the year of diagnosis, as 'nonlate' if their CD4 count was above 200, and as 'unknown' if CD4 cell count in the year at the time of diagnosis was not documented. Among the 4516 patients available for analysis, the percentage of late testing was 38% (n = 1718) and decreased after 2003 (31.5% in 2004-2005). This percentage was higher in heterosexual men (48.2%) than in homosexual men (31.7%) or heterosexual women (32.6%) and was higher for patients older than 30. Heterosexual men living in a couple with children had a higher risk of late testing (odds ratio [OR] = 1.65, 95% confidence interval [CI]: 1.03 to 2.66), while heterosexual women in a couple without children had a lower risk (OR = 0.46, 95% CI: 0.25 to 0.83). Among homosexual men, unemployment was associated with late testing (OR = 2.23, 95% CI: 1.14 to 4.36). The proportion of late testing was still high. Groups classically identified as low risk for HIV infection, particularly heterosexual men in a couple with children, were found to be at high risk for late testing. It seems necessary to improve HIV testing policy in the heterosexual population.

Published
2006

22. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Author

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, and Harousseau, Jean-Luc

Published
2012
Full Text
View/download PDF

23. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial

Author

Perrot, Aurore, primary, Lauwers-Cances, Valerie, additional, Cazaubiel, Titouan, additional, Facon, Thierry, additional, Caillot, Denis, additional, Clement-Filliatre, Lauriane, additional, Macro, Margaret, additional, Decaux, Olivier, additional, Belhadj, Karim, additional, Mohty, Mohamad, additional, Karlin, Lionel, additional, Eisenmann, Jean Claude, additional, Tiab, Mourad, additional, Orsini, Frederique, additional, Touzeau, Cyrille, additional, Leleu, Xavier, additional, Avet-Loiseau, Herve, additional, Munshi, Nikhil C., additional, Anderson, Kenneth, additional, Richardson, Paul G., additional, Moreau, Philippe, additional, and Attal, Michel, additional

Published
2020
Full Text
View/download PDF

27. Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Author

Roussel, Murielle, primary, Hebraud, Benjamin, additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Facon, Thierry, additional, Boyle, Eileen, additional, Touzeau, Cyrille, additional, Pegourie, Brigitte, additional, Perrot, Aurore, additional, Stoppa, Anne-Marie, additional, Marolleau, Jean-Pierre, additional, Moreau, Philippe, additional, Avet-Loiseau, Herve, additional, Devlamynck, Laure, additional, Lauwers-Cances, Valerie, additional, and Attal, Michel, additional

Published
2019
Full Text
View/download PDF

28. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, Munshi, Nikhil, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil

Abstract

The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.

Published
2018

29. Using Poisson-gamma model to evaluate the duration of recruitment process when historical trials are available

Author

Minois, Nathan, Lauwers-Cances, Valerie, Savy, Stephanie, Attal, Michel, Andrieu, Sandrine, Anisimov, Vladimir, Savy, Nicolas, Institut de Mathématiques de Toulouse UMR5219 (IMT), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Service d'Epidémiologie, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Laboratoire de Microbiologie Appliquée de Quimper (LUMAQ), Université de Brest (UBO), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Service Epidémiologie clinique et santé publique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[STAT.ME]Statistics [stat]/Methodology [stat.ME], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

30. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma

Author

Attal, Michel, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean-Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle M.E., Zeytoonjian, Andrea A.A., Weller, Edie E.A., Lauwers-Cances, Valerie, Munshi, Nikhil, Anderson, Kenneth Carl, Richardson, Paul P.G., Facon, Thierry, Avet-Loiseau, Herve, Harousseau, Jean-Luc, Moreau, Philippe, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, Belhadj, Karim, Attal, Michel, Garderet, Laurent, Roussel, Murielle, Payen, Catherine, Mathiot, Claire, Fermand, Jean-Paul, Meuleman, Nathalie, Rollet, Sandrine, Maglio, Michelle M.E., Zeytoonjian, Andrea A.A., Weller, Edie E.A., Lauwers-Cances, Valerie, Munshi, Nikhil, Anderson, Kenneth Carl, Richardson, Paul P.G., Facon, Thierry, Avet-Loiseau, Herve, Harousseau, Jean-Luc, Moreau, Philippe, Hulin, Cyrille, Leleu, Xavier, Caillot, Denis, Escoffre, Martine, Arnulf, Bertrand, Macro, Margaret, and Belhadj, Karim

Abstract

BACKGROUND High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation. METHODS We randomly assigned 700 patients with multiple myeloma to receive induction therapy with three cycles of RVD and then consolidation therapy with either five additional cycles of RVD (350 patients) or high-dose melphalan plus stem-cell transplantation followed by two additional cycles of RVD (350 patients). Patients in both groups received maintenance therapy with lenalidomide for 1 year. The primary end point was progression-free survival. RESULTS Median progression-free survival was significantly longer in the group that underwent transplantation than in the group that received RVD alone (50 months vs. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001). This benefit was observed across all patient subgroups, including those stratified according to International Staging System stage and cytogenetic risk. The percentage of patients with a complete response was higher in the transplantation group than in the RVD-Alone group (59% vs. 48%, P = 0.03), as was the percentage of patients in whom minimal residual disease was not detected (79% vs. 65%, P<0.001). Overall survival at 4 years did not differ significantly between the transplantation group and the RVD-Alone group (81% and 82%, respectively). The rate of grade 3 or 4 neutropenia was significantly higher in the transplantation group than in the RVD-Alone group (92% vs. 47%), as were the rates of grade 3 or 4 gastrointestinal disorders (28% vs. 7%) and infections (20% vs. 9%). No significant between-group differences were observed in the rates of treatmentrelated deaths, second primary cancers, thromboembol, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

31. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Author

Attal, Michel, primary, Lauwers-Cances, Valerie, additional, Hulin, Cyrille, additional, Leleu, Xavier, additional, Caillot, Denis, additional, Escoffre, Martine, additional, Arnulf, Bertrand, additional, Macro, Margaret, additional, Belhadj, Karim, additional, Garderet, Laurent, additional, Roussel, Murielle, additional, Payen, Catherine, additional, Mathiot, Claire, additional, Fermand, Jean P., additional, Meuleman, Nathalie, additional, Rollet, Sandrine, additional, Maglio, Michelle E., additional, Zeytoonjian, Andrea A., additional, Weller, Edie A., additional, Munshi, Nikhil, additional, Anderson, Kenneth C., additional, Richardson, Paul G., additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Harousseau, Jean-Luc, additional, and Moreau, Philippe, additional

Published
2017
Full Text
View/download PDF

33. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Author

Attal, Michel, primary, Palumbo, Antonio, additional, Holstein, Sarah A., additional, Lauwers-Cances, Valerie, additional, Petrucci, Maria Teresa, additional, Richardson, Paul G., additional, Hulin, Cyrille, additional, Tosi, Patrizia, additional, Anderson, Kenneth Carl, additional, Caillot, Denis, additional, Magarotto, Valeria, additional, Moreau, Philippe, additional, Marit, Gerald, additional, Yu, Zhinuan, additional, and McCarthy, Philip L., additional

Published
2016
Full Text
View/download PDF

34. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Author

Attal, Michel, primary, Lauwers-Cances, Valerie, additional, Hulin, Cyrille, additional, Facon, Thierry, additional, Caillot, Denis, additional, Escoffre, Martine, additional, Arnulf, Bertrand, additional, MACRO, Margaret, additional, Belhadj, Karim, additional, Garderet, Laurent, additional, Roussel, Murielle, additional, Mathiot, Claire, additional, Avet-Loiseau, Herve, additional, Munshi, Nikhil C., additional, Richardson, Paul G., additional, Anderson, Kenneth C., additional, Harousseau, jean Luc, additional, and Moreau, Philippe, additional

Published
2015
Full Text
View/download PDF

35. Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial

Author

Avet-Loiseau, Herve, primary, Corre, Jill, additional, Lauwers-Cances, Valerie, additional, Chretien, Marie-Lorraine, additional, Robillard, Nelly, additional, Leleu, Xavier, additional, Hulin, Cyrille, additional, Gentil, Catherine, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Brechignac, Sabine, additional, Garderet, Laurent, additional, Karlin, Lionel, additional, Marit, Gerald, additional, Benboubker, Lotfi, additional, Orsini-Piocelle, Frederique, additional, Royer, Bruno, additional, Drenou, Bernard, additional, Tiab, Mourad, additional, Lamy, Thierry, additional, MACRO, Margaret, additional, Richardson, Paul G., additional, Anderson, Kenneth C, additional, Faham, Malek, additional, Facon, Thierry, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Munshi, Nikhil C., additional

Published
2015
Full Text
View/download PDF

36. Sarcopenia, calf circumference, and physical function of elderly women: a cross-sectional study

Author

Rolland, Yves, Lauwers-Cances, Valerie, Cournot, Maxime, Nourhashemi, Fati, Reynish, William, Riviere, Daniel, Vellas, Bruno, and Grandjean, Helene

Subjects
Physical fitness -- Demographic aspects, Musculoskeletal diseases -- Demographic aspects, Musculoskeletal diseases -- Diagnosis, Extremities, Lower -- Physiological aspects, Leg -- Physiological aspects, Aged women -- Health aspects, Health, Seniors
Abstract

Results show that calf circumference is not an effective predictor of sarcopenia, or loss of musculoskeletal mass, in elderly women. However, it does offer valuable information on physical function and muscle-related disability for this population.

Published
2003

38. Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

Author

Roussel, Murielle, Hebraud, Benjamin, Lauwers-Cances, Valerie, Macro, Margaret, Leleu, Xavier, Hulin, Cyrille, Karlin, Lionel, Royer, Bruno, Perrot, Aurore, Moreau, Philippe, Caillot, Denis, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Pegourie, Brigitte, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean Valere, Dorvaux, Veronique, Lenain, Pascal, Benbrahim, Omar, Jaccard, Arnaud, Borel, Cecile, Avet Loiseau, Herve, and Attal, Michel

Published
2017
Full Text
View/download PDF

39. A Higher Risk of Acute Rejection of Human Kidney Allografts Can Be Predicted from the Level of CD45RC Expressed by the Recipients’ CD8 T Cells

Author

Ordonez, Laurence, primary, Bernard, Isabelle, additional, Chabod, Marianne, additional, Augusto, Jean-François, additional, Lauwers-Cances, Valerie, additional, Cristini, Christelle, additional, Cuturi, Maria-Cristina, additional, Subra, Jean-François, additional, and Saoudi, Abdelhadi, additional

Published
2013
Full Text
View/download PDF

40. 1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients

Author

Hebraud, Benjamin, primary, Leleu, Xavier, additional, lauwers-Cances, Valerie, additional, Roussel, Murielle, additional, Marit, Gerald, additional, Karlin, Lionel, additional, Hulin, Cyrille, additional, Gentil, Catherine, additional, Guilhot, Francois, additional, Garderet, Laurent, additional, Lamy, Thierry, additional, Brechignac, Sabine, additional, Pegourie, Brigitte, additional, Jaubert, Jerome, additional, Dib, Mamoun, additional, Stoppa, Anne-Marie, additional, Sebban, Catherine, additional, Fohrer, Cecile, additional, Fontan, Jean, additional, Fruchart, Christophe, additional, Bouscary, Didier, additional, Corront, Bernadette, additional, Lepeu, Gerard, additional, Corre, Jill, additional, Facon, Thierry, additional, Attal, Michel, additional, Moreau, Philippe, additional, and avet-Loiseau, Herve, additional

Published
2012
Full Text
View/download PDF

41. Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study

Author

Avet-Loiseau, Hervé, primary, Caillot, Denis, additional, Marit, Gerald, additional, Lauwers-Cances, Valerie, additional, Roussel, Murielle, additional, Facon, Thierry, additional, Hulin, Cyrille, additional, Lamy, Thierry, additional, Pegourie, Brigitte, additional, Maisonneuve, Herve, additional, Garderet, Laurent, additional, Moreau, Philippe, additional, Stoppa, Anne-Marie, additional, Dib, Mamoun, additional, Jaubert, Jerome, additional, Casassus, Philippe, additional, Mathiot, Claire, additional, Harousseau, Jean-Luc, additional, and Attal, Michel, additional

Published
2010
Full Text
View/download PDF

45. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Krd Phase II Study

Author

Roussel, Murielle, Lauwers-Cances, Valerie, Robillard, Nelly, Belhadj, Karim, Facon, Thierry, Garderet, Laurent, Escoffre, Martine, Pegourie, Brigitte, Benboubker, Lotfi, Caillot, Denis, Fohrer, Cecile, Moreau, Philippe, Leleu, Xavier, Avet-Loiseau, Herve, and Attal, Michel

Abstract

Roussel: BMS: Other: lecture fees; sanofi: Other: lecture fees; AMGEN: Consultancy, Other: lecture fees, Research Funding; celgene: Consultancy, Other: lecture fees, Research Funding; janssen: Consultancy, Other: lecture fees. Belhadj:janssen: Consultancy; novartis: Consultancy. Facon:celgene: Consultancy; janssen: Consultancy; sanofi: Consultancy; BMS: Consultancy; novartis: Consultancy; amgen: Consultancy. Garderet:Novartis: Consultancy; Takeda: Consultancy; Amgen: Consultancy; BMS: Consultancy, Honoraria. Fohrer:celgne: Consultancy; amgen: Consultancy. Moreau:Janssen: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria; Amgen: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Celgene: Honoraria. Leleu:TEVA: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; LeoPharma: Honoraria; Pierre Fabre: Honoraria; Amgen: Honoraria; Bristol-Myers Squibb: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Avet-Loiseau:celgene: Consultancy; amgen: Consultancy; sanofi: Consultancy; janssen: Consultancy. Attal:amgen: Consultancy, Research Funding; celgene: Consultancy, Research Funding; janssen: Consultancy, Research Funding; sanofi: Consultancy.

Published
2016
Full Text
View/download PDF

46. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease

Author

Johnatan Ceccom, Claude Alain Maurage, Yvan Nicaise, Olivier Cuvillier, Stuart M. Pitson, Charles Duyckaerts, Valérie Lauwers-Cances, Marie-Bernadette Delisle, Catherine Gentil, Najat Loukh, Christian Touriol, Emmanuelle Uro-Coste, Service d'Anatomie Pathologique, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Service d'Epidémiologie, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre for Cancer Biology, SA Pathology, Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc - U837 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université Lille 2 - Faculté de Médecine, Service de Pathologie, Université Lille Nord (France)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Institut de pharmacologie et de biologie structurale (IPBS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), This work was supported by a grant from the Clinical Research Hospital Program from the French Ministry of Health (PHRC 2010, n° 18_02) and the Fondation Plan Alzheimer., Service Anatomie et cytologie pathologiques [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Epidémiologie clinique et santé publique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Ceccom, Johnatan, Loukh, Najat, Lauwers-, Cances Valerie, Touriol, Christian, Nicaise, Yvan, Gentil, Catherine, Uro-Coste, Emmanuelle, Pitson, Stuart, Maurage, Claude Alain, Duyckaerts, Charles, Cuvillier, Olivier, Delisle, Marie-Bernadette, and BMC, Ed.

Subjects
Male, Statistics as Topic, chemistry.chemical_compound, 0302 clinical medicine, Receptor, Neuropathology, Aged, 80 and over, Neurons, 0303 health sciences, sphingoising1-phosphate lyase-neuropatholgy, Neurodegeneration, Brain, Sphingosine kinase-1, Middle Aged, Alzheimer's disease, Cell biology, Sphingosine 1-phosphate lyase, Phosphotransferases (Alcohol Group Acceptor), Biochemistry, Sphingosine kinase 1, sphingosine kinase-1, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Alzheimer’s disease, Alzheimer ' s disease, Signal Transduction, beta amyloid, Biology, Pathology and Forensic Medicine, 03 medical and health sciences, Cellular and Molecular Neuroscience, Alzheimer Disease, medicine, Humans, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Sphingosine-1-phosphate, Aged, Aldehyde-Lyases, 030304 developmental biology, Sphingolipids, Amyloid beta-Peptides, sphingolipids, Sphingosine, Cell growth, Research, Beta amyloid, Lipid signaling, medicine.disease, Sphingolipid, Gene Expression Regulation, chemistry, biology.protein, Neurology (clinical), 030217 neurology & neurosurgery
Abstract

International audience; BACKGROUND: The accumulation of beta amyloid (Aβ) peptides, a hallmark of Alzheimer's disease (AD) is related to mechanisms leading to neurodegeneration. Among its pleiotropic cellular effects, Aβ accumulation has been associated with a deregulation of sphingolipid metabolism. Sphingosine 1-phosphate (S1P) derived from sphingosine is emerging as a critical lipid mediator regulating various biological activities including cell proliferation, survival, migration, inflammation, or angiogenesis. S1P tissue level is low and kept under control through equilibrium between its synthesis mostly governed by sphingosine kinase-1 (SphK1) and its degradation by sphingosine 1-phosphate lyase (SPL). We have previously reported that Aβ peptides were able to decrease the activity of SphK1 in cell culture models, an effect that could be blocked by the prosurvival IGF-1/IGF-1R signaling. RESULTS: Herein, we report for the first time the expression of both SphK1 and SPL by immunohistochemistry in frontal and entorhinal cortices from 56 human AD brains. Immunohistochemical analysis revealed a decreased expression of SphK1 and an increased expression of SPL both correlated to amyloid deposits in the entorhinal cortex. Otherwise, analysis of brain tissue extracts showed a decrease of SphK1 expression in AD brains whereas SPL expression was increased. The content of IGF-1R, an activator of SphK1, was found decreased in AD brains as well as S1P1, the major receptor for S1P. CONCLUSIONS: Collectively, these results highlight the importance of S1P in AD suggesting the existence of a global deregulation of S1P signaling in this disease from its synthesis by SphK1 and degradation by SPL to its signaling by the S1P1 receptor.

Published
2014

47. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.

Author

Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien ML, Moreau P, Facon T, Leleu X, Karlin L, Stoppa AM, Decaux O, Belhadj K, Arnulf B, Mohty M, Ariette CM, Fohrer-Sonntag C, Lenain P, Marolleau JP, Tiab M, Araujo C, Orsini-Piocelle F, Jaccard A, Roussel M, Benboubker L, Eveillard JR, Dib M, Divoux M, Attal M, Avet-Loiseau H, and Corre J

Subjects
Humans, Neoplasm Staging, Prognosis, Proportional Hazards Models, Chromosome Aberrations, Multiple Myeloma pathology
Abstract

In the era of personalized treatment in multiple myeloma, high-risk patients must be accurately identified. The International Myeloma Working Group recommends using the Revised International Staging System (R-ISS) to pick out high-risk patients. The main purpose of our work was to explore the heterogeneity of outcome among R-ISS stage II patients assessing the impact of International Staging System (ISS) stage, chromosomal abnormalities and lactate dehydrogenase level in this subgroup. Data were collected from 1,343 patients up to 65 years old with newly diagnosed myeloma, enrolled in three clinical trials implemented by the Intergroupe Francophone du Myélome. All patients were eligible for intensive treatment. Patients in R-ISS stage II but ISS stage I had 1.6 times higher risk of death than patients in R-ISS stage I (adjusted hazard ratio=1.6; 95% confidence interval: 1.1-2.2; P=0.01) and patients in R-ISS stage II but with ISS stage III had a better overall survival than patients in R-ISS stage III (adjusted hazard ratio=0.7; 95% confidence interval: 0.4-0.9, P=0.02). However, among patients classified in R-ISS II, ISS stage and chromosomal abnormalities (del[17p] and t[4;14]) were still relevant prognostic factors for death. Dividing R-ISS stage II into three subgroups: ISS I with standard-risk chromosomal abnormalities, ISS II or III with standard-risk chromosomal abnormalities and patients with high-risk chromosomal abnormalities, median overall survival times were, respectively, not reached, 112 months and 71 months (P<0.001). In conclusion, stratification of patients in the R-ISS stage II group can be improved by taking into account chromosomal abnormalities and ISS. However, this does not improve predictive performance of survival models.

Published
2023
Full Text
View/download PDF

48. [Evolution of psychosocial factors in a cohort of HIV-infected patients adherent to therapy].

Author

Delmas P, Coté J, Delpierre C, Sylvain H, Lauwers-Cances V, and Delon S

Subjects
Adaptation, Psychological, Adult, Cognition, Female, France, HIV Infections complications, HIV Infections drug therapy, Health Status, Humans, Longitudinal Studies, Male, Mental Health, Models, Psychological, Nursing Methodology Research, Patient Compliance statistics & numerical data, Psychiatric Status Rating Scales, Severity of Illness Index, Social Behavior, Stress, Psychological diagnosis, Stress, Psychological prevention & control, Stress, Psychological psychology, Surveys and Questionnaires, Time Factors, Urban Population, Anti-HIV Agents therapeutic use, HIV Infections psychology, Patient Compliance psychology, Quality of Life psychology
Abstract

At the present time, one of the main problems encountered by patients living with HIV is related to the notion of therapy adherence. In this context, quality of life appears to be an essential variable, because it seems correlated to adherent behavior. Mannheimer et al (2005) have indeed shown in a longitudinal study that adherent patients maintained a high level of quality of life over time. However, the long-term evolution of psychosocial variables related to quality of life in adherent patients at the time of their inclusion is not known. This study therefore aims, through longitudinal follow-up of a cohort of adherent patients, at describing the evolution over time of psychosocial factors related to their quality of life. The sample was constituted from the HIV-infected population consulting in the respective wards of six cities in the Midi-Pyrénées region (France). Inclusion criteria were set according to objective and subjective criteria of adherence as recommended by literature. The sample size was 133 individuals at T0 and 110 individuals at T1, which is compatible with chosen statistical requirements (two-tailed alpha risk 5%, study power 80%, SD 20). The results show a significant decrease over time of mental health and health perceptions in adherent patients. Moreover, at 6 months, results reveal, in patients who are no longer adherent, higher scores across several dimensions of stress and a decrease of their mental health level in comparison to adherent patients. It seems living with the HIV for patients having an adherent behavior has repercussions over time, thus inducing a degree of frailty on the mental health level. Also, in adherent patients becoming non-adherent over time, the stress variable appears as essential.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results